- Sequel Med Tech and Senseonics (SENS, Financial) collaborate to launch the first Automated Insulin Delivery (AID) System with a one-year Continuous Glucose Monitor (CGM).
- The integrated system will be compatible with Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus and is expected to launch in Q3 2025.
- Eversense 365 has secured FDA iCGM clearance as of September 2024, paving the way for this innovative partnership.
Sequel Med Tech and Senseonics Holdings, Inc. (SENS) have announced a strategic partnership aimed at revolutionizing diabetes care with the development of the first Automated Insulin Delivery (AID) System compatible with a one-year Continuous Glucose Monitor (CGM). This collaboration integrates Sequel’s twiist™ AID System with Senseonics’ Eversense 365, a unique CGM with an unprecedented one-year duration.
The partnership is poised to enhance diabetes management tools significantly, offering patients with type 1 diabetes greater flexibility and personalization. The twiist system will be compatible not only with Eversense 365 but also with Abbott’s FreeStyle Libre 3 Plus sensor, broadening its applicability and patient choice.
Regulatory developments have cleared the path for this collaboration, with the Eversense 365 obtaining FDA clearance as an integrated continuous glucose monitoring (iCGM) system in September 2024. This paves the way for its integration into automated insulin delivery systems, promising improved glucose control and convenience for users.
This innovative system is anticipated to launch in the third quarter of 2025 and is expected to significantly impact how diabetes is managed, offering a comprehensive solution by combining long-duration glucose monitoring with advanced insulin delivery technologies.
